Literature DB >> 6250063

Co-infection by lactic dehydrogenase virus and C-type retrovirus elicits neurological disease.

L R Pease, W H Murphy.   

Abstract

Intraperitoneal injection of neuropathogenic strains of lactic dehydrogenase virus (LDV) causes a histologically distinctive fatal paralytic disease characterized by an inflammatory destruction of motor neurones in the brain stem and cord in C58 mice aged over 9 months. To elicit the disease in the naturally susceptible C58 strain requires an age-associated or X-ray induced loss of immunological competence, LDV infection and genetic susceptibility. Genetic studies of the common inbred mouse strains showed that susceptibility to the disease was not linked to the major histocompatibility complex but correlated with the FV-1n allele, susceptibility to spontaneous leukaemia, and infection by neuropathogenic strains of LDV. These observations suggested that neuropathogenic strains of LDV elicit the disease only in those strains of mice that carry multiple copies of N-tropic C-type retroviruses in their genomes and that are permissive for retrovirus replication. Presumably the expression of these viral genomes (high titres of virus in tissues correlating with age) is the important factor. Here we present genetic evidence to support this hypothesis and briefly discuss the possible implications.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250063     DOI: 10.1038/286398a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  13 in total

1.  A paradigm for virus-induced demyelinating disease.

Authors:  T Christensen
Journal:  Trends Microbiol       Date:  1997-04       Impact factor: 17.079

Review 2.  Neurologic syndromes associated with retroviral infections: current views.

Authors:  W H Murphy
Journal:  Surv Immunol Res       Date:  1983

3.  Age-related loss of Lyt-1,2 cells in C58 mice results in susceptibility to lactic dehydrogenase virus-induced polioencephalomyelitis.

Authors:  D M Bentley; S R Watson; R E Morris
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  Monoclonal antibody protection from age-dependent poliomyelitis: implications regarding the pathogenesis of lactate dehydrogenase-elevating virus.

Authors:  J T Harty; P G Plagemann
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Poliomyelitis in MuLV-infected ICR-SCID mice after injection of basement membrane matrix contaminated with lactate dehydrogenase-elevating virus.

Authors:  Jodi A Carlson Scholz; Rohit Garg; Susan R Compton; Heather G Allore; Caroline J Zeiss; Edward M Uchio
Journal:  Comp Med       Date:  2011-10       Impact factor: 0.982

6.  Age-dependent poliomyelitis of mice: expression of endogenous retrovirus correlates with cytocidal replication of lactate dehydrogenase-elevating virus in motor neurons.

Authors:  C H Contag; P G Plagemann
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

7.  Retrovirus antigens in brains of mice with scrapie- and murine leukemia virus-induced spongiform encephalopathy.

Authors:  P M Hoffman; O M Pitts; R G Rohwer; D C Gajdusek; S K Ruscetti
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

8.  Comparison of the ability of lactate dehydrogenase-elevating virus and its virion RNA to infect murine leukemia virus-infected or -uninfected cell lines.

Authors:  T Inada; H Kikuchi; S Yamazaki
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Infection of central nervous system cells by ecotropic murine leukemia virus in C58 and AKR mice and in in utero-infected CE/J mice predisposes mice to paralytic infection by lactate dehydrogenase-elevating virus.

Authors:  G W Anderson; G A Palmer; R R Rowland; C Even; P G Plagemann
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  B lymphocyte activation by coinfection prevents immune control of friend virus infection.

Authors:  Rute Marques; Inês Antunes; Urszula Eksmond; Jonathan Stoye; Kim Hasenkrug; George Kassiotis
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.